EGFR and adenocarcinoma: In adenocarcinoma, several driver mutations have been identified, including mutations/alterations of the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS1, among others; most of them are therapeutically targetable [4].